CeMM is currently home to 8 Core Principal Investigators and 12 Adjunct Principal Investigators, all exploring fundamental questions in molecular medicine. CeMM’s scientific excellence is reflected in its outstanding record of competitive funding. The research teams include 11 recipients of prestigious European Research Council (ERC) grants, spanning Starting Grants (Clarissa Campbell, Florian Grebien, Barbara Maier, Davide Seruggia, Georg Winter), Consolidator Grants (Andreas Bergthaler, Christoph Bock, Kaan Boztug, Stefan Kubicek, Nuno Maulide, Georg Winter), and Advanced Grants (Giulio Superti-Furga, Andreas Villunger, Nuno Maulide). CeMM was also a core contributor to major Innovative Medicines Initiative (IMI) projects, such as IMI RESOLUTE and IMI REMEDi4ALL (Giulio Superti-Furga).
Together we pioneer science that nurtures precise, personalized, predictive, and preventative medicine
In line with CeMM’s mission to advance precise, personalized, predictive, and preventive medicine, we maintain a deep integration with the clinical world. Three of our Adjunct PIs – Kaan Boztug, Thomas Reiberger, and Georg Stary – are clinician-scientists actively combining patient care with cutting-edge research. Ihave a dual affiliation with the Medical University of Vienna: Andreas Bergthaler, Christoph Bock, Kaan Boztug, Georg Busslinger, Vanja Nagy, Thomas Reiberger, Georg Stary and Giulio Superti-Furga. Andreas Villunger is affiliated with the Medical University of Innsbruck, Kaan Boztug, Florian Grebien and Davide Seruggia with the Children's Cancer Research Institute (CCRI) in Vienna.
CeMM thrives on interdisciplinary collaboration, recognizing the power of integrating chemistry, physics, and network science to unlock new biomedical insights. Therefore, our Adjunct PIs Nuno Maulide and Jörg Menche are jointly affiliated with the University of Vienna, while Miriam Unterlass bridges chemistry and materials science through her affiliation with the Fraunhofer-Institute in Würzburg.
